PERSERIS KIT
LOE ApproachingNDASUBCUTANEOUSFOR SUSPENSION, EXTENDED RELEASE
Approved
Jul 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERSERIS KIT is a subcutaneous, extended-release small molecule suspension approved in 2018 by Indivior. The exact indication and mechanism of action are not specified in available data, but the product represents an innovative delivery formulation approach. The kit format suggests patient convenience and adherence optimization.
LOE Approaching1.4 years to LOE
Product approaching loss of exclusivity in ~1.4 years; commercial teams face transition from growth to defense and line extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on PERSERIS KIT at Indivior? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.